Protagonist Therapeutics (PTGX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Protagonist Therapeutics (PTGX) do?
Protagonist Therapeutics Inc (PTGX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops synthetic peptide drugs targeting blood disorders and inflammatory diseases through clinical trials. Designs synthetic peptide medicines that mimic or block protein targets usually treated with larger antibodies. It is worth $8.09B on the market and sold $551.79M over the last year.
- Market cap
- $8.09B
- P/E ratio
- 26.3×
- Annual sales
- $551.79M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 12, 2026
PTGX’s flags, in plain English
Each flag is a number from Protagonist Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Stupid Cash
Can pay this year's bills 19.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Fat Margins
Profit margin of 62%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Heavily Shorted
16.6% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about PTGX
How big is Protagonist Therapeutics?
Protagonist Therapeutics’ market cap is $8.09B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $551.79M: what customers paid the company over the last year, before any costs.
What is PTGX’s P/E ratio?
PTGX’s P/E ratio is 26.3×. Investors pay about 26.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with PTGX?
Revenue depends heavily on milestone payments from development partners Janssen and Takeda rather than recurring commercial drug sales. That is one risk on Protagonist Therapeutics’ card. Its first risk flag is Heavily Shorted, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Protagonist Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PTGX’s filings on SEC.gov. The Margin Monkey is research, not advice.
